PD-L1 IHC 28-8 pharmDx
Agilent Technologies, Inc. · Decision date Sep 21, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-21 for PMA supplement P150025/S019, associated with PD-L1 IHC 28-8 pharmDx and submitted by Agilent Technologies, Inc. The supplement was filed as a 30-Day Notice under the reason category Process Change - Manufacturer/Sterilizer/Packager/Supplier. The recorded statement describes approval of a supplier's change to the manufacturing site for a device component.
This action concerns a manufacturing supply change for one component of the device rather than a new approval of the assay system as a whole. The source record does not identify the specific component, the supplier, the old or new manufacturing site, or any supporting documents, and it lists no device category or product code. The specialty field is Pathology. Whether the change carries clinical or analytical implications for assay performance is not stated in the available data.
The date shown is the recorded decision date in this source and should be verified against the FDA record before use in regulatory or compliance documentation. No patient-selection thresholds, testing instructions or performance claims are part of this supplement record.
FDA approval order statement
approval for a supplier's change to the manufacturing sight for a device component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150025/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
- Decision code
- OK30
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
For the original device and its historical approval scope, see PMA P150025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150025 · Original PMA
PD-L1 IHC 28-8 pharmDx
P150025/S019 received
Application receipt date recorded by FDA.
P150025/S020 · Related supplement
PD-L1 IHC 28-8 pharmDx
P150025/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 28-8 pharmDxP150025 | Agilent Technologies, Inc. | PMA approval | Oct 9, 2015 | FDA |
PD-L1 IHC 28-8 pharmDxP150025/S020 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150025/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
